Nektar Therapeutics | NKTR - 销售和管理费用



金融业
股票价格
USD 37.72
资产
USD 763.27M
现金及等价物
USD 149.58M
销售成本
USD 4.44M
流动资产
USD 589.04M
流动负债
USD 57.71M
债务
USD 0
股息收益率
0
EBIT
USD -38.26M
EBITDA
USD -38.9M
员工
137
EPS每股收益
USD -1.78
股本和储备
USD 576.22M
销售毛利
USD 10.86M
债务利息支出
USD 7.94M
利息收入
USD -0.18
贷款资金
USD 60.27M
市值
USD 7.05B
净收入
USD -44.9M
营业费用
USD 49.12M
营业利润
USD -38.26M
普通股股本
USD 29.47M
税前利润
USD -43.09M
销售收入
USD 10.86M
销售和管理费用
USD 11.87M
股票
USD 14.46M
贸易债权人
USD 10.03M
应收帐款人
USD 3.6M


销售和管理费用 更改 日
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 196.64M 67.96M 2026-06
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
Amgen USD 1.72B 134M 2026-06
Baxter International USD 735M 7M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 709.7M 155.4M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Cara Therapeutics USD 2.09M 96K 2026-03
Cipla INR 13.25B 101.8M 2025-12
Dr.Reddys Laboratories INR 26.1B 11.63B 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Exelixis USD 147.63M 8.03M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 57M 10.71M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Karyopharm Therapeutics USD 10.42M 861K 2026-03
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.89B 219M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Pfizer USD 3.41B 496M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Takeda JPY 286.51B 5.48B 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Xencor USD 77.54M 4.59M 2026-06